Company Overview and News

11
Dividend Sensei's Portfolio Update 55: Why I Love Stock Market Corrections

2018-10-16 seekingalpha - 2
Unlike most investors, who fear sharply falling prices, I become most excited when the market runs deep red.
TXN UNIT AQN SHLD IRM BLK NBLX BRX OHI KIM

 
NBLX / Noble Midstream Partners LP / Salient Capital Advisors, LLC - null (Passive Investment)

2018-10-10 sec.gov
UNITED STATES* SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* Noble Midstream Partners LP ------------------------------------------------ (Name of Issuer) Common Units Representing Limited Partner Interests ------------------------------ (Title of Class of Securities)
NBLX

 
NBLX / Noble Midstream Partners LP / Salient Capital Advisors, LLC - null (Passive Investment)

2018-10-10 sec.gov
UNITED STATES* SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* Noble Midstream Partners LP ------------------------------------------------ (Name of Issuer) Common Units Representing Limited Partner Interests ------------------------------ (Title of Class of Securities)
NBLX

 
Noble Midstream, Salt Creek to Build Pipeline System in Delaware Basin

2018-10-04 rigzone
Salt Creek Midstream, LLC and Noble Midstream Partners LP have entered into a joint venture to create a crude oil pipeline and gathering system in the Delaware Basin.
NBLX

1
Dividend Sensei's Portfolio Update 53: The Only 3 Reasons You Should Sell A Stock

2018-10-02 seekingalpha
There are 3 reasons to ever sell a stock: the thesis breaks, you need the money to cover expenses, or it no longer meets your long-term portfolio goals.
ENB NBLX TXN BPY DM UNIT AMGP ENB OHI HCLP

11
Week Thoughts: Update From Zombieland

2018-10-01 seekingalpha
As if stuck on repeat, oil and natural gas were up, midstream was down this week. The S&P 500 paused its upward trajectory, and utilities were negative for a second straight week. Income securities had a rough month generally, and it feels like midstream is being painted with the "income stock" brush rather than the "energy stock" brush.
BKEP TGE AMID PAGP WGP SEP ANDX AM EQM NBLX EQGP OKE EEP FGP MPLX TLP ENLK GLNG SE ETP TCP GMLP DM WES SEMG

3
Dividend Sensei's Portfolio Update 52: What I'll Be Buying During The Next Bear Market

2018-09-25 seekingalpha
The core strategy of my portfolio is to maximize safe yield, fast payout growth, and buy what's most on sale.
NBLX NBL AAPL

2
Dividend Sensei's Portfolio Update 51: Annual Performance Review

2018-09-19 seekingalpha
The first year saw large volatility and a modest profit. However, I underperformed the market thanks to three early mistakes.
HD OMP NBLX OAS UNIT SPG

1
Water In The (Mid)Stream: How Water Flows Generate Cash Flows

2018-09-19 seekingalpha
Your elementary science teacher probably taught you that oil and water don't mix, but when it comes to oil production, water plays an important role. In fact, water is both a necessity and a potential headache for oil and natural gas producers. Water is needed for hydraulic fracturing of wells, which involves pumping water, chemicals and sand into a well to open fractures to encourage production of hydrocarbons.
NGL AM NBLX APA ALDW CTLR CLR ALJ AR

20
Dividend Sensei's Portfolio Update 50: The Best 5 High-Yield Monthly-Paying Dividend Stocks To Buy Today

2018-09-12 seekingalpha
However, while there are many monthly payers available, few are a good source of generous, safe, and steadily rising income.
NBLX GEC GE NBL GNE BSTI AMGP

3
Record Earnings, Rising Guidance, 20% Distribution Growth, And A Well-Covered 7.5% Yield

2018-09-01 seekingalpha
Management committed to 20% annual distribution guidance through 2021, and raised its guidance for EBITDA and for distribution coverage.
AM OMP EQM OAS NBLX SHLX HESM VLP CNXM BPMP PSXP

1
Dividend Sensei's Portfolio Update 47: Overcoming Adversity And Soaring To New Heights

2018-08-13 seekingalpha
It's the two-year anniversary of my coming home to Minnesota after a disastrous five years that destroyed my: finances, confidence, and marriage.
AM OMP MPLX EQM NBLX DM NEP

2
Noble Midstream Partners LP (NBLX) CEO Terry Gerhart on Q2 2018 Results - Earnings Call Transcript

2018-08-03 seekingalpha
Noble Midstream Partners LP (NYSE:NBLX) Q2 2018 Earnings Conference Call August 3, 2018 11:00 AM ET
NBLX NBL BDIMF BDE BDI

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 65506L105